Skip to main content

Advertisement

Table 2 Summary baseline characteristics of the eligible study population

From: Using fractional exhaled nitric oxide (FeNO) to diagnose steroid-responsive disease and guide asthma management in routine care

Baseline characteristics Study population n = 678
Sex: male n (%) 313 (46.2)
Age: median (IQR) 46 (26, 60)
BMI, median (IQR) 26.0 (22.9, 30.6)
Rhinitis diagnosis or therapy, n (%) 305 (45.0)
Smoking status, n (%) Current Smoker 40 (5.9)
  Ex-smoker 145 (21.4)
  Non-smoker 477 (70.4)
Exacerbations, n (%) 0 551 (81.3)
  1 83 (12.2)
  ≥2 44 (6.5)
SABA dose (mcg), n (%) 1-100 121 (17.8)
  101-200 132 (19.5)
  201-400 94 (13.9)
  401+ 47 (6.9)
Average ICS Daily dose, (mcg) BDP-equivalent dose, n (%) None 304 (44.8)
  1-100 67 (9.9)
  101-200 106 (15.6)
  201-400 101 (14.9)
  401+ 100 (14.7)
Asthma therapy, n (%) None 193 (28.5)
  SABA 101 (14.9)
  ±SABA LTRA 8 (1.2%)
   ICS 182 (26.8)
   ICS + LABA 136 (20.1)
   ICS + LAMA 1 (0.1)
  ±SAMA ICS + LABA + LAMA 5 (0.7)
   ICS + LTRA 8 (1.2)
   ICS + LABA + LTRA 42 (6.2)
  Other 2 (0.3)